Current Role of Brivaracetam in the Management of Epilepsy in Adults . . . The landscape of epilepsy treatment has evolved significantly, encompassing pharmaceutical agents, implantable devices, and surgical interventions Antiepileptic drugs (AEDs) remain the cornerstone of epilepsy treatment, and about 70% of patients achieve effective seizure control through medication alone [10]
BRIVIACT Ratings Reviews by Doctors | Uses Side Effects BRIVIACT is generally effective for controlling partial seizures, with physicians noting its good efficacy and safety ratings However, side effects can vary significantly among patients, impacting overall tolerability Accessibility and affordability are significant concerns for BRIVIACT, as some patients report that the price acts as a barrier to accessing this medication
Briviact (Brivaracetam) - The Defeating Epilepsy Foundation Brivaracetam, also known as Briviact, is a third-generation anticonvulsant with improved tolerability and safety compared to first-generation drugs, such as Phenytoin and Carbamazepine (Moseley et al , 2020) It is approved for treating partial-onset seizures in patients as young as one month old (U S Food and Drug Administration, 2016)
A review of the pharmacology and clinical efficacy of brivaracetam Abstract Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive treatment of focal (partial-onset) seizures in adults BRV is a selective, high-affinity ligand for synaptic vesicle 2A (SV2A) with 15- to 30-fold higher affinity than levetiracetam, the first AED acting on SV2A It has high lipid solubility and rapid brain penetration, with engagement of the target